Biophytis Reports 2020 Full Year Results
(0.28) Summary of operational events (more details are provided in the corresponding press releases available on Biophytis's website: www.biophytis.com) Launch of the Phase 2-3 COVA study in patients with severe respiratory manifestation of COVID-19 In May 2020, Biophytis received approval from the Belgian Federal Agency for Medicines and Health Products (FAMHP), to proceed with its clinical development program COVA, a two-part study assessing Sarconeos (BIO101) in patients aged 45 and older, hospitalized with severe respiratory manifestations following COVID-19 infection; Biophytis recei...
Source: einnews.com